BioSpaceOriginal article
Insmed Scraps Skin Plans for Lung Disease Drug as Competitors Make Headway
Phase 2negativeBrinsupriNegative
AI Analysis
Summary
Insmed discontinued development of Brinsupri for hidradenitis suppurativa following a Phase 2 clinical failure, while competitors Incyte, Novartis, and UCB advance in the same indication.
Clinical Trial Data
Phase
Phase 2
Primary Endpoint
Not Met
Outcome Details
Phase 2 trial failure led to discontinuation of development for hidradenitis suppurativa indication
Importance:5/10
Sentiment:
-0.80
clinical_trial_failureprogram_discontinuationhidradenitis_suppurativacompetitive_landscape
Read the original article
Published by BioSpace on April 8, 2026 12:00 PM